Coronary and Peripheral Stents Market: Rising Prevalence of Cardiovascular Diseases to Drive Market Growth to US$ 20,230.87 Million by 2033.

As per the latest market research by Business Market Insights (BMI), the research report" Coronary and Peripheral Stents Market Size and Forecast (2025–2033)" forecasts how the market is set to surge 116.89% by 2033. The global coronary and peripheral stents market is primarily driven by the rising prevalence of cardiovascular diseases, including coronary artery and peripheral artery conditions, coupled with the growth of the geriatric population. Technological advancements such as drug-eluting and bioresorbable stents, along with a shift toward minimally invasive procedures, are boosting adoption. Additionally, expanding healthcare infrastructure, improved diagnostic awareness, supportive reimbursement frameworks, and rising demand in emerging markets are key growth enablers.

The report forecasts the market to expand from US$ 9,327.81 million in 2024 to US$ 20,230.87 million by 2033, registering a robust CAGR of 8.98% over the 2025–2033 period.

The global coronary and peripheral stents market is witnessing robust growth, fueled by increasing prevalence of cardiovascular and peripheral artery diseases, particularly among the aging population. Stents, including drug-eluting, bare-metal, and bioresorbable variants, are widely used to restore blood flow and prevent arterial blockages. Technological advancements, such as improved stent designs and minimally invasive deployment techniques, are enhancing procedural outcomes and patient recovery. Rising awareness of cardiovascular health, better diagnostic facilities, and supportive reimbursement frameworks are further boosting adoption. Additionally, expanding healthcare infrastructure in emerging regions and growing demand for personalized interventional therapies are contributing to market expansion. The market is marked by innovation, increasing procedural volumes, and evolving clinical practices globally.

Overview of report findings

Market Growth

The coronary and peripheral stents market is projected to grow from US$ 9,327.81 million in 2024 to US$ 20,230.87 million by 2033, registering a compound annual growth rate (CAGR) of 8.98% between 2025 and 2033.

The global coronary and peripheral stents market is primarily driven by the rising prevalence of cardiovascular diseases, including coronary artery and peripheral artery conditions, coupled with the growth of the geriatric population. Technological advancements such as drug-eluting and bioresorbable stents, along with a shift toward minimally invasive procedures, are boosting adoption. Additionally, expanding healthcare infrastructure, improved diagnostic awareness, supportive reimbursement frameworks, and rising demand in emerging markets are key growth enablers.

Rising Prevalence of Cardiovascular Diseases

The global increase in cardiovascular diseases (CVDs), including coronary artery disease (CAD) and peripheral artery disease (PAD), is a major driver for the stents market. Sedentary lifestyles, unhealthy diets, obesity, diabetes, and hypertension contribute to the growing disease burden, particularly in both developed and emerging economies. As these conditions lead to arterial blockages, stent implantation becomes a critical intervention to restore blood flow and prevent complications such as heart attacks, strokes, or limb ischemia. The rise in diagnostic awareness and routine cardiovascular screenings ensures early detection, resulting in a higher number of patients eligible for stent procedures. Additionally, the expanding geriatric population, which is more susceptible to CVDs, further increases procedural volumes, directly boosting the demand for both coronary and peripheral stents across global healthcare settings.

Shift Toward Minimally Invasive Procedures

Minimally invasive procedures, particularly percutaneous coronary interventions (PCI) and endovascular treatments for peripheral arteries, are rapidly replacing traditional open surgeries, driving stent adoption. These procedures offer significant advantages, including reduced procedural risks, shorter hospital stays, faster recovery, and lower post-operative complications. The availability of advanced stents, such as drug-eluting and bioresorbable stents, enhances the safety and efficacy of these interventions, encouraging physicians to prefer stenting over surgical bypass. Minimally invasive approaches also support higher procedural throughput in hospitals and catheterization laboratories, making interventions more accessible to a larger patient base. Furthermore, growing patient preference for less invasive treatment options, combined with increasing healthcare infrastructure and trained specialists, contributes to the rising demand for stents, reinforcing their role as a cornerstone in modern cardiovascular care.

Geographic Insights

North America dominates the coronary and peripheral stents market due to high surgical procedure volumes, early adoption of advanced stapling technologies, and widespread use of minimally invasive and robotic surgeries. Strong hospital infrastructure, high penetration of disposable surgical consumables, and established reimbursement systems support consistent reload usage. Surgeons’ preference for premium, procedure-specific reloads further strengthens demand across hospitals and ambulatory surgical centers.

Europe is the second-largest market for stents, supported by a growing geriatric population and increasing prevalence of cardiovascular diseases. Countries such as Germany, France, and the UK have well-developed healthcare systems and high procedural capacities. The adoption of advanced stents, including drug-eluting and bioresorbable stents, along with increasing awareness of minimally invasive interventions, contributes to steady market growth. Favorable reimbursement policies further encourage the use of coronary and peripheral stents across the region.

Asia Pacific is the fastest-growing market for coronary and peripheral stents due to rising cardiovascular disease prevalence, urbanization, and lifestyle changes. Expanding healthcare infrastructure, increasing availability of catheterization labs, and growing access to advanced stent technologies drive adoption. Countries such as China, India, and Japan are witnessing rapid procedural growth, supported by rising awareness, improving diagnostic facilities, and supportive government initiatives promoting cardiovascular interventions, making this region a key growth hub globally.

Market Segmentation

• By product type, the coronary and peripheral stents market is segmented into bare-metal stents, drug-eluting stents, bioresorbable vascular scaffolds, and others. The drug-eluting stents segment dominated the market in 2024. Superior efficacy in reducing restenosis, longer-term patient outcomes, and widespread physician preference drove adoption, making them the most trusted choice compared to bare-metal or bioresorbable alternatives.
• By material type, the coronary and peripheral stents market is segmented into metal, polymer, and hybrid. The metal segment dominated the market in 2024. High durability, proven biocompatibility, cost-effectiveness, and established clinical success ensured dominance, as polymer and hybrid options remain limited in availability, scalability, and long-term performance validation.
• By application, the coronary and peripheral stents market is segmented into coronary artery disease and peripheral artery disease. The coronary artery disease segment dominated the market in 2024. Higher global prevalence, significant clinical burden, and greater demand for interventional procedures positioned coronary stents as the leading application, overshadowing peripheral artery disease interventions in overall market share.
• By end user, the market is segmented into hospitals, ambulatory surgical centers, cardiac catheterization labs, and specialty clinics. The hospitals segment held the largest share of the market in 2024. Comprehensive infrastructure, advanced catheterization facilities, skilled specialists, and ability to handle complex cases ensured hospitals remained the primary setting for stent implantation, surpassing smaller clinics and ambulatory centers.

Competitive Strategy & Development

Key Players: The coronary and peripheral stents market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Medtronic
2. Boston Scientific Corporation
3. Abbott
4. B. Braun SE
5. TERUMO CORPORATION
6. Teleflex Incorporated
7. Lepu Medical Technology (Beijing) Co. Ltd.
8. Cook Medical
9. Meril Life Sciences
10. Translumina

Trending Topics: Interventional Catheters, PTCA Balloons, Guidewires and Introducer Sheaths, Transcatheter Heart Valves

Global Headlines

• Abbott Launches Next-Generation XIENCE Sierra™ Stent in India – In May 2024, Abbott, a global healthcare company, announced the launch of XIENCE Sierra™ Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE™ family for people suffering from blocked coronary arteries.
• Medtronic announced launch of Onyx Frontier™ drug-eluting stent (DES) – In August 2024, Medtronic announced that it has launched its newest drug-eluting coronary stent, the Onyx Frontier™ drug-eluting stent (DES), following recent CE Mark approval.

Conclusion

The global coronary and peripheral stents market is poised for continued growth, driven by increasing prevalence of cardiovascular and peripheral artery diseases, especially among the aging population. Technological advancements, such as drug-eluting, bioresorbable, and next-generation stents, are improving procedural outcomes and patient recovery, encouraging wider adoption. Minimally invasive interventions, expanding healthcare infrastructure, and growing awareness of cardiovascular health further support market expansion. North America and Europe maintain strong demand due to established healthcare systems, while Asia Pacific shows the fastest growth, fueled by rising disease prevalence and improving access to advanced therapies. Overall, the market is characterized by innovation, increasing procedural volumes, and a focus on patient-centric, efficient, and less invasive treatment solutions globally.